24 |
Klinisk Biokemi i Norden · 4 2013
of the pharmacokinetic, pharmacodynamic
and safety interaction between apixaban and
enoxaparin in healthy subjects. Thromb Hae-
most 2012;107:916-24.
12. Samama MM, Martinoli JL, LeFlem L, Gui-
net C, Plu-Bureau G, Depasse F, Perzborn E.
Assessment of laboratory assays to measure
rivaroxaban--an oral, direct factor xa inhibi-
tor. Thromb Haemost 2010;103:815-25.
13. Harenberg J, Giece C, Marx S. The point
of care monitor coagucheck-xs displays the
lowest coefficient of variation for determina-
tion of rivaroxaban compared to prothrombin
time and chromogenic assays. Abstract 52rd
ASH Annual Meeting and Exposition 2011.
14. Baruch L, Sherman O. Potential inaccuracy
of point-of-care inr in dabigatran-treated
patients. Ann Pharmacother 2011;45:e40.
15. DeRemer CE, Gujral JS, Thornton JW, Sor-
rentino RA. Dabigatran falsely elevates point
of care international normalized ratio results.
Am J Med 2011;124:e5-6.
16. van Ryn J, Stangier J, Haertter S, Liesenfeld KH,
WienenW, Feuring M, Clemens A. Dabigatran
etexilate--a novel, reversible, oral direct throm-
bin inhibitor: Interpretation of coagulation
assays and reversal of anticoagulant activity.
Thromb Haemost 2010;103:1116-27.
17. Favaloro EJ, Bonar R, Butler J, Marsden K.
Laboratory testing for the new oral anticoagu-
lants: A review of current practice. Pathology
2013;45:435-7.
18. Samama MM, Guinet C. Laboratory assess-
ment of new anticoagulants. Clin Chem Lab
Med 2011;49:761-72.
19. Gerotziafas GT, Baccouche H, Sassi M, Galea
V, Chaari M, Hatmi M, et al. Optimisation
of the assays for the measurement of clotting
factor activity in the presence of rivaroxaban.
Thromb Res 2012;129:101-3.
20. Asmis LM, Alberio L, Angelillo-Scherrer A,
Korte W, Mendez A, Reber G, et al. Rivaroxa-
ban: Quantification by anti-fxa assay and influ-
ence on coagulation tests: A study in 9 swiss
laboratories. Thromb Res 2012;129:492-8.
21. Favaloro EJ, Lippi G, Koutts J. Laboratory
testing of anticoagulants: The present and the
future. Pathology 2011;43:682-92.
22. Barrett YC, Wang Z, Frost C, Shenker A.
Clinical laboratory measurement of direct
factor xa inhibitors: Anti-xa assay is preferable
to prothrombin time assay. Thromb Haemost
2010;104:1263-71.
23. Becker RC, Alexander JH, Newby LK, Yang
H, Barrett Y, Mohan P, et al. Effect of apixa-
ban, an oral and direct factor xa inhibitor,
on coagulation activity biomarkers following
acute coronary syndrome. Thromb Haemost
2010;104:976-83.
24. Sanchez J, Diaz D, Bottenus R, Triscott M.
Effect of fxa inhibitors (apixaban and rivarox-
aban), thrombin inhibitors (dabigatran) and
fondaparinux on lupus anticoagulant tests
hemosil drvvt and sct. International Journal
of Laboratory Hematology 2012;34:168.
25. Merriman E, Kaplan Z, Butler J, Malan E,
Gan E, Tran H. Rivaroxaban and false positive
lupus anticoagulant testing. Thromb Haemost
2011;105:385-6.
26. Adcock DM, Gosselin R, Kitchen S, Dwyre
DM. The effect of dabigatran on select spe-
cialty coagulation assays. Am J Clin Pathol
2013;139:102-9.
27. Halbmayer WM, Weigel G, Quehenberger P,
Tomasits J, Haushofer AC, Aspoeck G, et al.
Interference of the new oral anticoagulant
dabigatran with frequently used coagulation
tests. Clin Chem Lab Med 2012;50:1601-5.
28. Douxfils J, Chatelain C, Chatelain B, Dogne
JM, Mullier F. Impact of apixaban on rou-
tine and specific coagulation assays: A prac-
tical laboratory guide. Thromb Haemost
2013;110:283-94.
29. Perzborn E, Roehrig S, Straub A, Kubitza D,
Misselwitz F. The discovery and development
of rivaroxaban, an oral, direct factor xa inhi-
bitor. Nat Rev Drug Discov 2011;10:61-75.
